Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Aug 28;1(2):129–146. doi: 10.1016/j.jacasi.2021.08.003

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2021 The Authors

This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

PMC Copyright notice

SGLT2 Inhibitors Versus GLP-1RAs on Kidney and Heart Failure

The bars represent absolute effects of treatment per 1,000 patients treated for 5 years for patients at very low risk (no cardiovascular risk factors), low risk (3 or more cardiovascular risk factors), moderate risk (atherosclerotic cardiovascular disease), high risk (chronic kidney disease), and very high risk (atherosclerotic vascular disease plus chronic kidney disease). (A) Kidney failure: SGLT2 inhibitor and GLP-1RA compared with placebo. (B) Kidney failure: SGLT2 inhibitor compared with GLP-1RA. (C) Hospitalization for heart failure: SGLT2 inhibitor and GLP-1RA compared with placebo. (D) Hospitalization for heart failure: SGLT2 inhibitor compared with GLP-1RA. Data adapted from Palmer et at (27) with permission. Abbreviations as in Figures 1 and 2.